Correction of Experimental Retinal Ischemia by L-Isomer of Ethylmethylhydroxypyridine Malate

An important task of pharmacology and ophtalmology is to find specific and highly effective agents for correcting retinal ischemia. The objective of this study is to increase the effectiveness of pharmacological correction of retinal ischemia by using new 3-hydroxypyridine derivative-L-isomer of ethylmethylhydroxypyridine malat

Interleukin-6 is a potential target for a correction of endothelial dysfunction associated with low-grade systemic inflammation

One of pathogenetic links of development of endothelial dysfunction, as an early marker of cardiovascular disease and comorbidity, is a low-grade systemic inflammation. In this regard, correction of cytokines imbalance is one of the possible ways of prevention and treatment of major chronic noninfectious diseases. To study the endothelium protective effects of anti-IL-6 receptor monoclonal antibodies tocilizumab in experimental preclinical studies in a model of endothelial dysfunction associated with the low-grade systemic inflammatio

Molecular screening of prospective candidates for TRPA₁ ion channel selective antagonists

Using the molecular modeling techniques, we analyzed spectra of biological activity of a series of promising candidates for selective antagonists of TRPA₁ ion channel in order to find potentially active compounds against pain and inflammatio

Retinoprotective effects of non-selective imidazoline receptor agonists

Current drug therapy of ophtalmic diseases associated with retinal ischemia is not always successful enough that ensures the relevance of the search of new effective drug

Ion channel TRPA₁ is a promising therapeutic target for treatment of pain

In the last time information about the role of TRPA₁ in pain and cold sensitivity, as well as in the formation and maintenance of inflammation is increasing in scientific literature. Given this information, the interest for search and study of pharmacological agents, which selectively blocked of TRPA₁ and reduced the severity of pain and inflammation is increasin

Preclinical study of pharmacological activity of enterosorbente on the basis of montmorillonite

At present, enterosorbents based on mineral raw materials are in high demand among the population. However, there are no enterosorbents on the Russian pharmaceutical market on the basis of domestic mineral raw materials, to study the pharmacological activity of enterosorbent based on montmorillonite of Russian origin under experimental conditions. The methodological approach was based on the implementation of a complex of theoretical, pharmacological, toxicological, histological, biochemical, statistical methods. Models of experimental diarrhea, acute and toxic liver damage, acute experimental pancreatitis were selecte

Studies to elucidate the effect and antiapoptotic mechanism of 2-ethyl-3-hydroxy-6- methylpyridine-n-acetyltaurinate in a rat model of retinal ischemia-reperfusion

To study the retinoprotective effect and antiapoptotic mechanism of 2-Ethyl-3-hydroxy-6-methyl-pyridine-Nacetyltaurinate (EHMP-NAT) in a rat model of retinal ischemia-reperfusio

Erythropoietin mimetic peptide (pHBSP) corrects endothelial dysfunction in a rat model of preeclampsia

Preeclampsia is a severe disease of late pregnancy. Etiological factors and a pathogenetic pattern of events still require significant clarification, but it is now recognized that a large role is played by placentation disorders and emerging endothelial dysfunction. The administration of short-chain peptides mimicking the spatial structure of the B erythropoietin chain may become one of the directions of searching for new drugs for preeclampsia prevention and therap

Аргиназа II - новая мишень для создания эндотелиопротекторов

The article describes arginase’s role in pathogenesis of endothelial dysfunction and a number of cardio-vascular diseases. Arginase catalyzes the hydrolysis of L-arginine, the substrate for nitric oxide synthesis, to L-ornithine and urea. Two isoforms of arginase were found in the human organism. Arginase I is located in the cells cytoplasm and is predominantly expressed in the liver. Arginase II is a mitochondrial protein that is expressed in the kidney, prostatic gland and vascular wall. Arginase II hydrolyzes L-arginine, thereby reducing the synthesis of nitric oxide and leading to the development of endothelial dysfunction and a number of cardio-vascular disorders. Arginase is a promising pharmacological target in the treatment of endothelial dysfunction and a number of cardio-vascular diseases, though the development of highly-selective arginase II inhibitors is still a difficult task.В обзоре рассмотрена роль аргиназы в патогенезе эндотелиальной дисфункции и ряда сердечно-сосудистых заболеваний. Аргиназа катализирует гидролиз L-аргинина, субстрата для синтеза оксида азота, до L-орнитина и мочевины. В организме человека обнаружены две изоформы аргиназы. Аргиназа I локализуется в цитоплазме клеток и экспрессируется преимущественно в печени. Аргиназа II - это митохондриальный белок, который экспрессируется в почках, простате, сосудистой стенке. Аргиназа II гидролизирует L-аргинин, снижая тем самым синтез оксида азота, приводит к развитию эндотелиальной дисфункции и возникновению целого ряда патологий сердечно-сосудистой системы. Аргиназа является перспективной фармакологической мишенью в коррекции эндотелиальной дисфункции и целого ряда сердечно-сосудистых заболеваний, однако создание высокоселективных ингибиторов аргиназы II по-прежнему остается трудноразрешимой задаче

Interleukin-6 is a potential target for a correction of endothelial dysfunction associated with low-grade systemic inflammation

One of pathogenetic links of development of endothelial dysfunction, as an early marker of cardiovascular disease and comorbidity, is a low-grade systemic inflammation. In this regard, correction of cytokines imbalance is one of the possible ways of prevention and treatment of major chronic noninfectious diseases. To study the endothelium protective effects of anti-IL-6 receptor monoclonal antibodies tocilizumab in experimental preclinical studies in a model of endothelial dysfunction associated with the low-grade systemic inflammatio